Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Amgen
ClinicalTrials.gov Identifier:
NCT00770536
First received: October 9, 2008
Last updated: October 9, 2014
Last verified: September 2014

October 9, 2008
October 9, 2014
January 2009
December 2014   (final data collection date for primary outcome measure)
The primary objective is to identify the incidence of adverse events and clinical laboratory abnormalities defined as dose limiting toxicity in subjects treated with AMG 386 + pegylated liposomal doxorubicin (cohort A) and with AMG 386 + topotecan [ Time Frame: first 4 weeks of treatment ] [ Designated as safety issue: Yes ]
The primary objective is to evaluate the incidence of adverse events and clinical laboratory abnormalities defined as dose limiting toxicity in subjects treated with AMG 386 + pegylated liposomal doxorubicin (cohort A) and with AMG 386 + topotecan [ Time Frame: (cohort first 4 weeks of treatment ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT00770536 on ClinicalTrials.gov Archive Site
  • To evaluate the treatment effect as measured by: objective response rate (ORR), duration of response (DOR), PFS, change in tumor burden, CA 125 Response and Progression by GCIG and CA-125 duration of response [ Time Frame: Treatment and follow-up phase of study ] [ Designated as safety issue: No ]
  • To evaluate the incidence of adverse events and clinical laboratory abnormalities not defined as DLTs. [ Time Frame: first 4 weeks of treatment ] [ Designated as safety issue: Yes ]
  • To determine the pharmacokinetics of pegylated liposomal doxorubicin (and its metabolite, doxorubicinol), topotecan and AMG 386 (Cmax, AUC, and Cmin for intensive assessment; Cmax and Cmin for sparse assessment). [ Time Frame: Treatment and follow-up phase of study ] [ Designated as safety issue: No ]
  • To estimate the incidence of anti AMG 386 antibody formation. [ Time Frame: Treatment and follow-up phase of study ] [ Designated as safety issue: Yes ]
  • To evaluate the incidence of adverse events and clinical laboratory abnormalities not defined as DLTs. [ Time Frame: first 4 weeks of treatment ] [ Designated as safety issue: Yes ]
  • To estimate the incidence of anti AMG 386 antibody formation. [ Time Frame: Treatment and follow-up phase of study ] [ Designated as safety issue: Yes ]
  • To evaluate the treatment effect as measured by: objective response rate (ORR), duration of response (DOR), PFS, change in tumor, CA 125 Response and Progression by Rustin Criteria; CA-125 duration of response [ Time Frame: Treatment and follow-up phase of study ] [ Designated as safety issue: No ]
  • To determine the pharmacokinetics of pegylated liposomal doxorubicin (and its metabolite, doxorubicinol), topotecan and AMG 386 (Cmax, AUC, and Cmin for intensive assessment; Cmax and Cmin for sparse assessment). [ Time Frame: Treatment and follow-up phase of study ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer

This study is a 2 part, 2 cohort, open-label, dose escalation/de escalation study of AMG 386 in combination with either pegylated liposomal doxorubicin or topotecan in subjects with recurrent ovarian cancer. Up to 100 subjects will be enrolled to receive AMG 386 in combination with either pegylated liposomal doxorubicin every 4 weeks (cohort A) or topotecan weekly on days 1, 8, and 15 of a 28 day dosing schedule (cohort B). Subject enrollment and assignment to either cohort will be based on eligibility and the investigator's discretion.

It is hypothesized that AMG 386, in combination with each of the chemotherapy regimens: either pegylated liposomal doxorubicin or topotecan will be safe and well tolerated in subjects with recurrent ovarian cancer.

The purpose of this study is to evaluate the effectiveness and safety of AMG 386 when used with pegylated liposomal doxorubicin or topotecan in subjects with advanced recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer

Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Cancer
  • Carcinoma
  • Fallopian Tube Cancer
  • Gynecological Malignancies
  • Metastases
  • Oncology
  • Ovarian Cancer
  • Solid Tumors
  • Tumors
  • Drug: A1: AMG 386 10 mg/kg + Liposomal doxorubicin
    Liposomal doxorubicin 50 mg/m2 IV Q4W in combination with AMG 386 10 mg/kg IV QW
    Other Names:
    • Liposomal doxorubicin
    • AMG 386
  • Drug: A3: AMG 386 15mg/kg + Liposomal doxorubicin
    A3: AMG 386 15 mg/kg IV QW + Liposomal doxorubicin 50 mg/m2 IV Q4W
    Other Names:
    • AMG 386
    • Liposomal doxorubicin
  • Drug: B1: AMG 386 10 mg/kg + Topotecan
    B1: AMG 386 10 mg/kg IV QW + Topotecan 4 mg/m2 IV days 1, 8, 15, of a 28 day dosing schedule
    Other Names:
    • Topotecan
    • AMG 386
  • Drug: B3: AMG 386 15mg/kg + Topotecan
    AMG 386 15mg/kg IV QW + Topotecan 4mg/m2 IV days 1, 8, 15 of a 28 day dosing schedule
    Other Names:
    • AMG 386
    • Topotecan
  • Experimental: Part 1
    In part 1, six subjects will be assigned to each cohort A or B. This is a dose escalation/de escalation study with a 6 + 3 design based on the incidence of DLTs (dose limiting toxicities) during the first 4 weeks of combined therapy [(cohort A: AMG 386 and pegylated liposomal doxorubicin) or (cohort B: AMG 386 and topotecan)].
    Interventions:
    • Drug: A1: AMG 386 10 mg/kg + Liposomal doxorubicin
    • Drug: A3: AMG 386 15mg/kg + Liposomal doxorubicin
    • Drug: B1: AMG 386 10 mg/kg + Topotecan
    • Drug: B3: AMG 386 15mg/kg + Topotecan
  • Experimental: Part 2
    The decision on declaration of a safe and tolerable dose during part 1 will lead to part 2 (cohort A: liposomal doxorubicin + AMG 386 MTD (max tolerated dose) of part 1, cohort B: Topotecan + AMG 386 MTD (max tolerated dose) of part 1
    Interventions:
    • Drug: A1: AMG 386 10 mg/kg + Liposomal doxorubicin
    • Drug: A3: AMG 386 15mg/kg + Liposomal doxorubicin
    • Drug: B1: AMG 386 10 mg/kg + Topotecan
    • Drug: B3: AMG 386 15mg/kg + Topotecan
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
103
December 2014
December 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically or cytologically documented recurrent invasive epithelial ovarian, fallopian tube, or primary peritoneal cancer
  • Subjects must have received at least one platinum containing regimen
  • Radiographically documented progression per RECIST criteria with modifications or progression of CA 125 as adopted by GCIG during or subsequent to the last chemotherapy regimen
  • Subjects may include those with measurable or non measurable disease
  • All scans and x-rays used to document measurable or non measurable disease must be done within 28 days prior to enrollment
  • Female 18 years of age or older at the time the written informed consent is obtained
  • GOG Performance Status of 0 or 1
  • Left Ventricular Ejection Fraction (LVEF) >= institutional lower limit of normal for subjects assigned to cohort A only
  • Adequate organ function as assessed by laboratory studies (hematological and chemistries)
  • Life expectancy >= 3 months (per investigator opinion)
  • Subjects of child bearing potential who have not undergone a bilateral salpingo oophorectomy and are sexually active must consent to use an accepted and effective double barrier non hormonal method of contraception from signing the informed consent through 6 months after last dose of study drug

Exclusion Criteria:

  • Subjects believed to be a higher than average risk of bowel perforation. This includes symptoms of partial or complete bowel obstruction, recent (within 6 months) history of fistula or bowel perforation, subjects requiring total parenteral nutrition and continuous hydration
  • Previous abdominal /or pelvic external beam radiotherapy
  • Known history of central nervous system metastases
  • Subjects with a history of prior malignancy, except:

    • Malignancy treated with curative intent and with no known active disease present for >= 3 years before study day 1 and felt to be at low risk for recurrence by treating physician
    • Adequately treated non melanomatous skin cancer or lentigo maligna without evidence of disease
    • Adequately treated cervical carcinoma in situ without evidence of disease
  • Prior myeloablative high dose chemotherapy with allogeneic or autologous stem cell (or bone marrow) transplant
  • History of arterial or deep venous thromboembolism within 12 months prior to enrollment
  • Clinically significant cardiac disease within 12 months prior to enrollment
  • Prior treatment with doxorubicin or pegylated liposomal doxorubicin (cohort A subjects) and topotecan (cohort B subjects)
  • Current or within 30 days prior to enrollment treatment with immune modulators such as systemic cyclosporine and tacrolimus
Female
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Australia,   Belgium
 
NCT00770536
20070182
No
Amgen
Amgen
Not Provided
Study Director: MD Amgen
Amgen
September 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP